The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes ...
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...